Dr. Reddy's : R&D coffer - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddy's : R&D coffer

May 30, 2001

Dr. Reddy’s has announced out-licensing of its diabetes molecule (DRF 4158) to Novartis. As per the terms of the agreement, Dr. Reddy would receive US$ 55 m in up front and milestone earnings. This is almost more than double its expected earnings for FY01. This milestone payment would be received prior to commercial launch of the molecule. While Novartis would have exclusive rights for worldwide development and commercialization, Dr. Reddy would have co-promotion rights for India. The company has been licensing its molecules to multinational companies for further development after conducting pre clinical studies, as part of its strategy to finance huge clinical trial costs. The company has already licensed two molecules (DRF-2725 and DRF 2593) in the anti-diabetes area to Novo Nordisk, a world leader in diabetic segment. The out-licensing has already earned the company, US$ 8 m till date. The huge milestone payment for the third molecule of US$ 55 m (Rs 2.6 bn approx.) is reflective of the company’s strength in pharma R&D. This is the largest ever milestone payment received by any pharma company in India.

Dr. Reddy’s strong research pipeline can be summarized as under.

Dr. Reddy’s R&D Coffer
Molecule Name Therapeutic
segment
Remarks
DRF 2593 Diabetes Licensed to Novo Nordisk.
Currently in Phase II of clinical trials
DRF 2725 Diabetes Licensed to Novo Nordisk.
Currently in Phase II of clinical trial in several
regulated markets including US and Europe.
Worldwide launch expected in 2004-05
DRF 4158 Diabetes Licensed to Novartis.
Pre-clinical already completed.
DRF NPPC Diabetes Pre-clinical completed.
Exploring licensing prospects.
DRF 1042 Cancer Phase I Clinical trial
DRF 1644 Cancer Currently, in pre-clinical studies
DRF ACXX Cancer Currently, in pre-clinical studies
DRF 4848 Pain Management Pre-clinical studies
DRF 4832 Cardiovascular Clinical trial contract given to
Simbec Research, UK

Further, proceeds from recently completed ADR are expected to be utilized for R&D activities. This would further strength the company’s pipeline. The company is expected to announce its consolidated results (with Cheminor drugs) on May 31, 2001. We expect the company to post an EPS of Rs 34.8, on a consolidated basis. Apart from the current windfall income and other positive news flow expected from its research pipeline, clear visibility of earnings from the US generic market is likely to create a positive impact on the stock price. At Rs 1,400, the stock trades at 40.2 and 33 times FY01 and FY02 expected earnings respectively (without taking into account extraordinary incomes like gains from US generic market and milestone payments).

Equitymaster requests your view! Post a comment on "Dr. Reddy's : R&D coffer". Click here!

  

More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

India's Best Semiconductor Stocks Views On News (Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better? (Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 20, 2022 09:58 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - ISTREET NETWORK COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS